DPP4 and chronic myelogenous leukemia, BCR-ABL1 positive: Moreover, immunological targeted therapy against these markers resulted in depletion of CML-LSC and reduce LSC engraftment.55 In a study of single-cell gene expression analysis combined with an immunophenotypic screening of CML-LSC, an aberrant expression of CML-LSC surface markers CD25, CD26, and interleukin1 receptor accessory protein (IL1RAP) was detected.